FRESENIUS SE & CO KGAA agreed to a biosimilars development partnership with WUXI BIOLOGICS CAYMAN INC on Monday morning, gaining exclusive access to 37 pipeline candidates. The German healthcare group will target originator sales exceeding €370 billion ($414 billion) over the next decade through the agreement. The collaboration expands the company's molecule count from 29 to as many as 66 by the next decade.

Expanding Biopharma Ambitions